vs
ADMA BIOLOGICS, INC.（ADMA）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
Proto Labs Inc的季度营收约是ADMA BIOLOGICS, INC.的1.0倍（$139.3M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 5.8%，领先29.7%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 10.4%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 5.3%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
ADMA vs PRLB — 直观对比
营收规模更大
PRLB
是对方的1.0倍
$139.2M
营收增速更快
ADMA
高出8.0%
10.4%
净利率更高
ADMA
高出29.7%
5.8%
两年增速更快
ADMA
近两年复合增速
5.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $139.3M |
| 净利润 | $49.4M | $8.1M |
| 毛利率 | 63.8% | 45.6% |
| 营业利润率 | 45.1% | 7.1% |
| 净利率 | 35.5% | 5.8% |
| 营收同比 | 18.4% | 10.4% |
| 净利润同比 | -55.9% | 125.4% |
| 每股收益（稀释后） | $0.20 | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAPRLB
| Q1 26 | — | $139.3M | ||
| Q4 25 | $139.2M | $136.5M | ||
| Q3 25 | $134.2M | $135.4M | ||
| Q2 25 | $122.0M | $135.1M | ||
| Q1 25 | $114.8M | $126.2M | ||
| Q4 24 | $117.5M | $121.8M | ||
| Q3 24 | $119.8M | $125.6M | ||
| Q2 24 | $107.2M | $125.6M |
净利润ADMAPRLB
| Q1 26 | — | $8.1M | ||
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $7.2M | ||
| Q2 25 | $34.2M | $4.4M | ||
| Q1 25 | $26.9M | $3.6M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $7.2M | ||
| Q2 24 | $32.1M | $4.5M |
毛利率ADMAPRLB
| Q1 26 | — | 45.6% | ||
| Q4 25 | 63.8% | 44.2% | ||
| Q3 25 | 56.3% | 45.3% | ||
| Q2 25 | 55.1% | 44.3% | ||
| Q1 25 | 53.2% | 44.1% | ||
| Q4 24 | 53.9% | 42.7% | ||
| Q3 24 | 49.8% | 45.6% | ||
| Q2 24 | 53.6% | 45.0% |
营业利润率ADMAPRLB
| Q1 26 | — | 7.1% | ||
| Q4 25 | 45.1% | 5.0% | ||
| Q3 25 | 38.0% | 6.5% | ||
| Q2 25 | 35.1% | 3.7% | ||
| Q1 25 | 30.4% | 3.6% | ||
| Q4 24 | 32.6% | -1.2% | ||
| Q3 24 | 33.1% | 6.8% | ||
| Q2 24 | 36.6% | 4.8% |
净利率ADMAPRLB
| Q1 26 | — | 5.8% | ||
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 5.3% | ||
| Q2 25 | 28.1% | 3.3% | ||
| Q1 25 | 23.4% | 2.9% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 5.7% | ||
| Q2 24 | 29.9% | 3.6% |
每股收益（稀释后）ADMAPRLB
| Q1 26 | — | $0.29 | ||
| Q4 25 | $0.20 | $0.25 | ||
| Q3 25 | $0.15 | $0.30 | ||
| Q2 25 | $0.14 | $0.18 | ||
| Q1 25 | $0.11 | $0.15 | ||
| Q4 24 | $0.45 | $-0.01 | ||
| Q3 24 | $0.15 | $0.29 | ||
| Q2 24 | $0.13 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $124.0M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $683.1M |
| 总资产 | $624.2M | $778.6M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAPRLB
| Q1 26 | — | $124.0M | ||
| Q4 25 | $87.6M | $128.1M | ||
| Q3 25 | $61.4M | $119.2M | ||
| Q2 25 | $90.3M | $103.2M | ||
| Q1 25 | $71.6M | $96.8M | ||
| Q4 24 | $103.1M | $103.1M | ||
| Q3 24 | $86.7M | $100.5M | ||
| Q2 24 | $88.2M | $112.9M |
总债务ADMAPRLB
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ADMAPRLB
| Q1 26 | — | $683.1M | ||
| Q4 25 | $477.3M | $673.9M | ||
| Q3 25 | $431.2M | $664.7M | ||
| Q2 25 | $398.3M | $664.7M | ||
| Q1 25 | $373.4M | $656.8M | ||
| Q4 24 | $349.0M | $670.2M | ||
| Q3 24 | $231.9M | $680.0M | ||
| Q2 24 | $188.3M | $685.2M |
总资产ADMAPRLB
| Q1 26 | — | $778.6M | ||
| Q4 25 | $624.2M | $763.4M | ||
| Q3 25 | $568.7M | $756.9M | ||
| Q2 25 | $558.4M | $743.3M | ||
| Q1 25 | $510.6M | $737.5M | ||
| Q4 24 | $488.7M | $743.5M | ||
| Q3 24 | $390.6M | $753.8M | ||
| Q2 24 | $376.4M | $758.2M |
负债/权益比ADMAPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $17.5M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | 2.16× |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMAPRLB
| Q1 26 | — | $17.5M | ||
| Q4 25 | $35.6M | $16.5M | ||
| Q3 25 | $13.3M | $29.1M | ||
| Q2 25 | $21.1M | $10.6M | ||
| Q1 25 | $-19.7M | $18.4M | ||
| Q4 24 | $50.2M | $17.3M | ||
| Q3 24 | $25.0M | $24.8M | ||
| Q2 24 | $45.6M | $14.4M |
自由现金流ADMAPRLB
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $8.4M | ||
| Q3 25 | $-1.1M | $25.0M | ||
| Q2 25 | $18.7M | $9.1M | ||
| Q1 25 | $-24.4M | $17.1M | ||
| Q4 24 | $47.5M | $16.5M | ||
| Q3 24 | $24.0M | $23.2M | ||
| Q2 24 | $43.6M | $10.2M |
自由现金流率ADMAPRLB
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 6.2% | ||
| Q3 25 | -0.8% | 18.5% | ||
| Q2 25 | 15.3% | 6.7% | ||
| Q1 25 | -21.2% | 13.6% | ||
| Q4 24 | 40.4% | 13.5% | ||
| Q3 24 | 20.0% | 18.5% | ||
| Q2 24 | 40.7% | 8.2% |
资本支出强度ADMAPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 5.9% | ||
| Q3 25 | 10.7% | 3.0% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 4.1% | 1.0% | ||
| Q4 24 | 2.3% | 0.7% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 1.9% | 3.3% |
现金转化率ADMAPRLB
| Q1 26 | — | 2.16× | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 4.03× | ||
| Q2 25 | 0.62× | 2.39× | ||
| Q1 25 | -0.73× | 5.11× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 3.44× | ||
| Q2 24 | 1.42× | 3.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
